Abstract:In the present study, we prepared a SCA3 animal model by generating transgenic mice expressing polyglutamine-expanded ataxin-3-Q79. Ataxin-3-Q79 was expressed in brain areas implicated in SCA3 neurodegeneration, including cerebellum, pontine nucleus and substantia nigra. Ataxin-3-Q79 transgenic mice displayed motor dysfunction with an onset age of 5–6 months, and neurological symptoms deteriorated in the following months. A prominent neuronal loss was not found in the cerebellum of 10 to 11-month-old ataxin-3-Q79 mice displaying pronounced ataxic symptoms, suggesting that instead of neuronal demise, ataxin-3-Q79 causes neuronal dysfunction of the cerebellum and resulting ataxia. To test the involvement of transcriptional dysregulation in ataxin-3-Q79-induced cerebellar malfunction, microarray analysis and real-time RT-PCR assays were performed to identify altered cerebellar mRNA expressions of ataxin-3-Q79 mice. Compared to non-transgenic mice or mice expressing wild-type ataxin-3-Q22, 10 to 11-month-old ataxin-3-Q79 mice exhibited downregulated mRNA expressions of proteins involved in glutamatergic neurotransmission, intracellular calcium signaling/mobilization or MAP kinase pathways, GABAA/B receptor subunits, heat shock proteins and transcription factor regulating neuronal survival and differentiation. Upregulated expressions of Bax, cyclin D1 and CDK5-p39, which may mediate neuronal death, were also observed in ataxin-3-Q79 transgenic mice. The involvement of transcriptional abnormality in initiating the pathological process of SCA3 was indicated by the finding that 4 to 5-month-old ataxin-3-Q79 mice, which did not display neurological phenotype, exhibited downregulated mRNA levels of genes involved in glutamatergic signaling and signal transduction. Our study suggests that polyglutamine-expanded ataxin-3 causes cerebellar dysfunction and ataxia by disrupting the normal pattern of gene transcriptions.

[Screening for Proteins Interacting with Ataxin-3, the Gene Product of SCA3/MJD].

Research on Screening and Identification of Proteins Interacting with Ataxin-3.

Covalent modification of ataxin-3 by SUMO-1

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

Casein Kinase 2 Interacts with and Phosphorylates Ataxin-3

PolyQ-expanded Ataxin-3 Interacts with Full-Length Ataxin-3 in a Polyq Length-Dependent Manner

Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation

Ataxin-3, the MJD1 Gene Product, Interacts with the Two Human Homologs of Yeast DNA Repair Protein RAD23, HHR23A and HHR23B

Fibril-forming motif of non-expanded ataxin-3 revealed by scanning proline mutagenesis

The BAG2 and BAG5 Proteins Inhibit the Ubiquitination of Pathogenic Ataxin3-80Q.

Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease

Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3

The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases

Polyglutamine-expanded ataxin-3 is degraded by autophagy

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.

Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3

Phosphorylation of Ataxin-3 by Glycogen Synthase Kinase 3β at Serine 256 Regulates the Aggregation of Ataxin-3

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics

Identification of a potential exosomal biomarker in spinocerebellar ataxia Type 3/Machado-Joseph disease.

Determining The Fate Of Neurons In Sca3: Atx3, A Rising Decision Maker In Response To Dna Stresses And Beyond

Recent Advances in Molecular Genetics of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease